Haselmeier, a part of medmix, has been established in the healthcare marketplace for over 100 years. With approximately 250 employees, Haselmeier has been pioneering the development of injection pens for subcutaneous application since the 1960s. We continue to drive innovation in self-injection pens from design and manufacturing to packaging and delivery. We have developed solutions in scalable volumes for numerous pharmaceutical partners, always following state-of-the-art engineering practices – and we aim to evolve even further. We design our products with a patient-centric approach. Our injection devices are used in a variety of therapeutic areas, helping patients living with diabetes, supporting fertility treatment and even being an option for low-impact cancer therapy